Cancer-Specific Survival Rates for NCCN High-Risk Prostate Cancer by Treatment Modality

Defining NCCN High-Risk Disease

The National Comprehensive Cancer Network (NCCN) defines high-risk prostate cancer by any of the following criteria: clinical stage T3a disease, Gleason score 8-10, or PSA >20 ng/mL 1, 2

The NCCN recommends external beam radiation therapy (EBRT) combined with long-term androgen deprivation therapy (ADT) for 2-3 years as the preferred treatment for high-risk prostate cancer, achieving 9-year disease-specific survival rates of 91% with trimodality therapy (EBRT + brachytherapy + ADT) 1, 3, 2, 4
The RTOG 92-02 trial demonstrated that long-term ADT (2+ years) with radiation achieved 45% overall survival at 10 years in Gleason 8-10 patients, compared to only 32% with short-term ADT (4 months) alone (P=0.0061) 3, 2

Trimodality therapy achieves the highest reported disease-specific survival rates, with 9-year progression-free survival of 87% and 9-year disease-specific survival of 91% 5, 4
Analysis of 12,745 high-risk patients showed brachytherapy plus EBRT lowered disease-specific mortality compared to EBRT alone (HR 0.77; 95% CI 0.66-0.90) 5, 4

Radical prostatectomy achieves only 36% progression-free survival for Gleason 8-10 disease 6, 3, 2
Surgery is appropriate only for selected patients with no fixation to adjacent organs 1, 6, 3

For standard high-risk disease, the NCCN recommends EBRT + long-term ADT (2-3 years) as first-line treatment, with alternative options including EBRT + brachytherapy ± ADT (2-3 years) and radical prostatectomy + PLND for selected cases 1, 3, 7

ADT duration is critical for survival benefit, with long-term ADT (2-3 years) required to achieve survival benefit 3, 2, 8
Brachytherapy monotherapy is contraindicated for high-risk disease, as it is inferior to EBRT or surgery 6, 2
ADT alone without radiation is insufficient for curative intent, and must be combined with radiation for high-risk disease 1, 6, 9

High‑risk prostate cancer is classified by the NCCN when any one of the following is present: clinical stage T3a (extracapsular extension), Gleason score 8–10, or PSA > 20 ng/mL. 10
Patients who meet multiple high‑risk criteria may be re‑classified as very high‑risk, which specifically requires clinical stage T3b–T4 (seminal‑vesicle invasion or invasion of adjacent structures). 10
Low‑risk disease (NCCN) is defined by clinical stage T1–T2a and Gleason ≤ 6 and PSA < 10 ng/mL. [10][11]
Intermediate‑risk disease (NCCN) is defined by clinical stage T2b–T2c or Gleason 7 or PSA 10–20 ng/mL. [10][11]12

Digital rectal examination is required to detect T3a disease (palpable extracapsular extension) or T3b–T4 disease (seminal‑vesicle or adjacent‑structure involvement). 10
Bone scan is recommended for all patients with Gleason 8–10, clinical stage T3–T4, or PSA > 20 ng/mL to rule out metastatic disease. (NCCN; supported by The Journal of Urology) [13][12]
Pelvic CT or MRI should be performed when PSA > 20 ng/mL, Gleason ≥ 8, or clinical stage T3–T4 to evaluate lymph‑node involvement. (NCCN; supported by The Journal of Urology) [13][12]

The ISUP Grade Group system re‑classifies Gleason 8 as Grade Group 4 and Gleason 9–10 as Grade Group 5. After radical prostatectomy, 5‑year biochemical‑recurrence‑free survival is approximately 48 % for Grade 4 and 26 % for Grade 5. (NCCN) 14
Gleason 9–10 disease (Grade 5) is associated with significantly poorer outcomes compared with Gleason 8 (Grade 4). (NCCN) 14

Brachytherapy monotherapy should not be used for high‑risk disease; it is inferior to external‑beam radiation therapy or radical prostatectomy in patients with Gleason pattern 4 or 5 or PSA > 10 ng/mL. (NCCN) 15
The distinction between high‑risk (T3a) and very high‑risk (T3b–T4) disease guides therapy: very high‑risk patients require a longer duration of androgen‑deprivation therapy. (NCCN) 10